认领应用
Vixilide®, a novel, best-in-class therapy for lung, neuroendocrine, and other cancers based on the proprietary somatostatin peptide conjugate P2045. Treatment with Vixilide represents a personalized approach, as between 80-90% of these patients are known to overexpress the target, somatostatin receptor 2, and the most appropriate patients having these tumors can be selected prior to therapy by imaging. This next generation approach rapidly kills cancer cells and spares healthy tissue.
成为钛媒体专业用户,即可查看联系方式
您是否确认要删除该条评论吗?
账号合并
经检测,你是“钛媒体”和“商业价值”的注册用户。现在,我们对两个产品因进行整合,需要您选择一个账号用来登录。无论您选择哪个账号,两个账号的原有信息都会合并在一起。对于给您造成的不便,我们深感歉意。
评论(0)